FISCHER MEDICAL VENTURES LTD (FISCHER): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1YAll

₹24.94 latest close · −36.5% over the last 90 sessions

₹24.94 month-end · −48.1% over 12 months

₹24.94 month-end · −74.2% since Jul '25

52-week range ₹21.78 to ₹109.01 · 1-year volatility 55.3%

Was the rally earned?

-48%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

Per-share earnings added 106 points, but investors now pay less per rupee of profit (P/E 534.2x to 65.6x), which took 154 points back.
The share count barely moved.

Net profit growth+107 ptsNet profit rose about 328%, which lifts the price.

P/E change-154 ptsThe P/E fell from 534.2x to 65.6x, which lowers the price.

Share count change-1 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with APOLLO HOSPITALS ENTERPRISES L

How rough has the ride been?

Maximum drawdown-79.7%not yet recovered

1-year volatility55.3%annualised

Volume spikes6last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-79.7% (2025-10 peak to 2026-10 low, not yet recovered)

-20.7% (2025-09 peak to 2025-10 low, recovered 2025-10)

Most recent volume spikes

2026-11-04: 5.1x the 50-day median, price +2.4% that day

2026-10-29: 5.6x the 50-day median, price -2.7% that day

2026-10-26: 7.1x the 50-day median, price +8.5% that day

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE22nd▲ 16 pts vs a year ago
Op. margin16th▼ 11 pts vs a year ago
Revenue growth97th
EPS growth100th
Debt/equity ↓58thflat vs a year ago
Cash cycle ↓69th▲ 57 pts vs a year ago
P/E ↓33rd▲ 30 pts vs a year ago
12M momentum9th

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What is the price implying?

~44%annual earnings growth implied by the price

At a P/E of 189.0x, the price would imply about 44.3%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Services The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹24.94
P/E: 65.6x
ROCE: 11.0%
Market Cap: ₹1742 cr
Revenue (TTM): ₹367 cr
P/S: 4.7x
P/B: 4.5x
ROE: 6.9%
Operating Margin: 13.7%
Debt / Equity: 0.3x
Promoter Holding: 62.1%
12M Momentum: -48.1%

52-week range

₹21.78₹109.01

4% of the way from its 52-week low to its high

Price risk

1Y volatility

55.3%

Beta vs sector

1-year daily

0.65

Balance sheet & cash

Interest cover

operating profit ÷ interest

5.4x

Cash from profit, 3Y

operating cash flow ÷ net profit

-2.00x

low

Share count, 1Y

+1.6%

Are profits backed by cash?

1 of 5checks within range2 beyond a threshold

Other income reliance15%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 15.0%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate39%Near threshold

Median quarterly effective tax rate over about 2.5 years: 38.8%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion-5.71xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: -5.71x (cash from operations ₹-194 cr, net profit ₹34 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow1 of 3 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 3: 1. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress9% of fixed assetsWithin range

Capital work-in-progress is 9% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Since Mar 2025, promoters trimmed 0.7 pts.
The number of shareholders rose from 10,180 to 23,950 (+135%) between Mar 2025 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupMar '25Jun '26Change

Promoters62.8%62.1%-0.7 pts

FIIs5.2%5.5%+0.3 pts

DIIs1.4%1.4%-0.1 pts

Public and others30.5%31.0%+0.5 pts

Number of shareholders

23,950shareholders+135% since Mar '25

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−11.5%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like FISCHER MEDICAL VENTURES LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −34% to +25% vs the market, against −7% for all non-financial companies in the same months.
The gap against the base rate (−4.7%, 80% range −15.1% to +2.8%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 4 beyond the range shown, drawn at the edge

Similar setups' median

−11.5%

All companies' median

−6.8%

Beat the market

36% vs 42%

50 past situations · 50 companies · 33 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
MICEL Health Technology	Jan 2023	83x	9%	−50%	−68%	+127%
URAVIDEF Electronic Technology	Sep 2025	107x	—	−49%	−60%	−53%
GENESYS Technology Services	Oct 2023	68x	7%	−40%	−44%	+77%
OPTIEMUS Distribution Services	Jun 2023	43x	14%	−26%	−42%	+3%
RESPONIND Non-Energy Minerals	Jul 2021	89x	6%	+41%	−31%	−2%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
GIRIRAJ Industrial Services	Feb 2025	63x	16%	−53%	−73%	−57%
DUGLOBAL Commercial Services	Oct 2025	66x	15%	−56%	−56%	−31%
HATHWAY Consumer Services	May 2021	44x	5%	+9%	−53%	−35%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: interest cover, P/S and ROCE. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to FISCHER MEDICAL VENTURES LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

PASHUPATI COTSPINPASHUPATI

Process Industries

66%similar

ROCEmarket cap

SAHASRA ELECTRONIC SOLUSAHASRA

Electronic Technology

62%similar

debt/equityP/E

FAZE THREEFAZE3Q

Process Industries

60%similar

ROCEvolatility

ALL TIME PLASTICSALLTIME

Producer Manufacturing

59%similar

operating marginROCE

TIRUPATI FORGETIRUPATIFL

Producer Manufacturing

59%similar

debt/equityvolatility

UNIHEALTH HOSPITALSUNIHEALTH

Health Services

26%similar

debt/equityvolatility

ARTEMIS MEDICARE SERVICESARTEMISMED

Health Services

24%similar

debt/equitypromoter holding

KOVAI MEDICAL CENTER & HOSPITAKOVAI

Health Services

20%similar

revenuevolatility

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

12 events since Aug '25

2026
OctPriceFell 80% from the Oct 2025 peak to the Oct 2026 low.
OctPriceVolume reached 17.1x its 50-day median on 2026-10-23; price +4.2% that day.
SepPriceVolume reached 6.6x its 50-day median on 2026-09-22; price +0.2% that day.
JunPeer rankSlipped to the bottom quartile of Health Services on operating margin (from the 3rd quartile).
JunDividendDividend payout cut from 22% to 1% of profit.
JunPriceVolume reached 9.6x its 50-day median on 2026-06-30; price +9.0% that day.
MarPeer rankMoved into the 3rd quartile of Health Services on operating margin (from the bottom quartile).
MarPriceVolume reached 7.7x its 50-day median on 2026-03-24; price +5.0% that day.

Show 4 earlier events

2025
DecPeer rankSlipped to the bottom quartile of Health Services on operating margin (from the 3rd quartile).
NovPriceVolume reached 28.2x its 50-day median on 2025-11-21; price -4.6% that day.
SepPeer rankMoved into the 3rd quartile of Health Services on operating margin (from the bottom quartile).
AugPriceVolume reached 7.0x its 50-day median on 2025-08-14; price +3.9% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history17 months · 2025-07 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	65.6x	₹367 cr	6.9%	11.0%	0.3x
2026-10	65.2x	₹367 cr	6.9%	11.0%	0.3x
2026-09	88.3x	₹367 cr	6.9%	11.0%	0.3x
2026-08	90.3x	₹308 cr	7.2%	11.0%	0.3x
2026-07	100.3x	₹308 cr	7.2%	11.0%	0.3x
2026-06	107.0x	₹308 cr	7.2%	11.0%	0.3x
2026-05	63.6x	₹260 cr	12.6%	1.0%	0.3x
2026-04	63.3x	₹260 cr	12.6%	1.0%	0.3x
2026-03	67.5x	₹260 cr	12.6%	1.0%	0.3x
2026-02	131.9x	₹171 cr	6.3%	1.0%	0.3x
2026-01	132.8x	₹171 cr	6.3%	1.0%	0.3x
2025-12	143.5x	₹171 cr	6.3%	1.0%	0.3x
2025-11	534.2x	₹124 cr	1.8%	1.0%	0.3x
2025-10	1307.9x	₹124 cr	1.8%	1.0%	0.3x
2025-09	1233.3x	₹124 cr	1.8%	1.0%	0.3x
2025-08	5285.0x	₹111 cr	0.4%	1.0%	0.3x
2025-07	4835.0x	₹111 cr	0.4%	1.0%	0.3x

Methodology and data notes